Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06398977
Status:
RECRUITING
Last Update Posted:
2024-05-03
First Post:
2024-04-16
Brief Title:
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
Sponsor:
Sichuan Academy of Medical Sciences
Organization:
Sichuan Academy of Medical Sciences
Study Overview
Official Title:
Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis A Single-Center Randomized Open-Label Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to explore the role of dagliflozin in preserving the residual renal functionRRF in peritoneal dialysis PD patients
Detailed Description:
Residual renal function RRF plays the role of removing water and body metabolic wastes as well as secretion of erythropoietin and promotion of vitamin D absorption which can maintain the stability of the internal environment Several studies have demonstrated that preservation of RRF in PD patients reduces complications increases dialysis adequacy and decreases mortality In addition residual renal function is an important factor in the technique survival Methods to protect residual renal function in peritoneal dialysis patients include controlling blood pressure controlling blood glucose adjusting dialysis prescription and using renin-angiotensin inhibitors However the above methods currently play only a limited role
Sodium-dependent glucose transporters 2 SGLT2 inhibitors are drugs used in the treatment of type 2 diabetes mellitus that inhibit the reabsorption of glucose by the kidneys causing glucose to be excreted in the urine and lowering blood glucose Studies have demonstrated that SGLT2 inhibitors also attenuate renal tubular injury reduce the excretion of proteinuria and have a protective effect on RRF in non-dialysis patients with chronic kidney disease However there are no clinical studies demonstrating whether the use of SGLT2 inhibitors in peritoneal dialysis patients is renal protective
In light of this this study introduces dagliflozin orally to PD patients over a 24-week period to explore its protective effects on RRF and cardiac health with participants being randomly divided into a dagliflozin group and a control group The results of this study will be beneficial in informing the clinical practice of SGLT2 inhibitors and improving dialysis outcomes in PD patients
Sodium-dependent glucose transporters 2 SGLT2 inhibitors are drugs used in the treatment of type 2 diabetes mellitus that inhibit the reabsorption of glucose by the kidneys causing glucose to be excreted in the urine and lowering blood glucose Studies have demonstrated that SGLT2 inhibitors also attenuate renal tubular injury reduce the excretion of proteinuria and have a protective effect on RRF in non-dialysis patients with chronic kidney disease However there are no clinical studies demonstrating whether the use of SGLT2 inhibitors in peritoneal dialysis patients is renal protective
In light of this this study introduces dagliflozin orally to PD patients over a 24-week period to explore its protective effects on RRF and cardiac health with participants being randomly divided into a dagliflozin group and a control group The results of this study will be beneficial in informing the clinical practice of SGLT2 inhibitors and improving dialysis outcomes in PD patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None